Edwards Lifesciences (EW) Tops Q2 EPS by 9c; Raises Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Edwards Lifesciences (EW) PT Raised to $120 at Oppenheimer
July 30, 2021 6:27 AM EDTOppenheimer analyst Suraj Kalia raised the price target on Edwards Lifesciences (NYSE: EW) to $120.00 (from $97.00) while maintaining an Outperform rating.
The analyst commented, "Edwards reported 2Q21 revenues of $1.38B vs. our/consensus' $1.29B/$1.28B estimates and guidance of $1.251.33B. TAVR revenues... More
